Clinical Trial Update: A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital) [EARLY_Phase 1]

View source ↗

Summary

Early-phase study evaluating GC201 TIL in advanced gynecologic tumors is currently recruiting across multiple hospitals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• GC201 TIL

Snippet

Sponsor: Shanghai Juncell Therapeutics | Conditions: Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL | EARLY_Phase 1 | Status: RECRUITING